About Pharmalex India Private Limited
Data last updated:
Pharmalex India Private Limited is a foreign private limited company based in New Delhi, Delhi, India, a subsidiary of Pharmalex Gmbh. It operates in the preventive healthcare segment of the healthcare sector. It was incorporated on 23 May 2013 and has been in existence for over 13 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U85100DL2013FTC252553. Its GSTIN is 07AAACY6178L1ZQ (Delhi). The company holds 3 GST registrations, all of them active.
The company has an authorised share capital of ₹20 Lakh and a paid-up capital of ₹20 Lakh. It was formerly known as Yes Regulatory Healthcare Services India Private Limited. It is led by directors Pawan Kumar Suri (Managing Director) and Christopher Gauglitz.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at A – 6/250, New Delhi, Delhi, India – 110063.
As per the financials filed for FY 2025, the company reported a revenue of ₹74.75 Cr, a decline of 8% compared to the previous year. For the same year it recorded a net profit of ₹5.79 Cr (net margin 7.7%) and EBITDA of ₹9.31 Cr (EBITDA margin 12.5%). Revenue has grown at a compounded annual rate (CAGR) of 10% over three years and 35% over five years.
The company has about 267 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: PharmaLex. The company has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹19 Lakh; the latest was in September 2016. Its 10 peer companies in the Healthcare industry (Preventive Healthcare Services) are compared by revenue, 5 larger and 5 smaller; the largest is Surabhi Healthcare & Research Private Limited with revenue of ₹82.7 Cr. The company has 2 MSME Form 1 returns on record for the period ending Mar 2023, listing 158 overdue payments to 4 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website pharmalex.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressA – 6/250, New Delhi, Delhi, India – 110063
- IndustryHealthcare, Preventive Health Services
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Pharmalex India Private Limited
The main business activity of Pharmalex India is professional, scientific and technical. In detail, this covers other professional, scientific and technical activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Pharmalex India Private Limited FY 2025 filings available
Pharmalex India Private Limited reported revenue of ₹74.75 Cr (down 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Pharmalex India Private Limited
Revenue fell 8% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 35%. EBITDA fell 39% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Pharmalex India Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹9.31 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹5.79 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Pharmalex India Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 12.5% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 7.7% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Pharmalex India are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Pharmalex India Private Limited
Pharmalex India Private Limited is compared with the companies closest to it by revenue in the Healthcare industry (Preventive Healthcare Services). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Surabhi Healthcare & Research Private Limited | ₹82.7 Cr (FY 2025) | •••• | •••• | 25.0% | •••• | Bangalore, Karnataka, India |
| Credent Connect N Care Limited | ₹82.54 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | New Delhi, Delhi, India |
| Goldwin Health Care Private Limited | ₹82.41 Cr (FY 2024) | •••• | •••• | 85.0% | •••• | Mumbai, Maharashtra, India |
| Sada Sharada Tumor and Research Institute | ₹80.93 Cr (FY 2025) | •••• | •••• | 39.0% | •••• | Karnataka, India |
| Med Care 365 Medical Services Private Limited | ₹79.85 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Mumbai, Maharashtra, India |
| Pharmalex India Private Limited this company | ₹74.75 Cr (FY 2025) | •••• | •••• | -8.0% | •••• | New Delhi, Delhi, India |
| SPGS Healthcare Private Limited | ₹74.04 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Pune, Maharashtra, India |
| Medwell Ventures Private Limited | ₹73.62 Cr (FY 2023) | •••• | •••• | -2.0% | •••• | New Delhi, Delhi, India |
| Sukino Healthcare Solutions Private Limited | ₹72.65 Cr (FY 2025) | •••• | •••• | 58.0% | •••• | Bangalore, Karnataka, India |
| Jindal Intellicom Limited | ₹70.83 Cr (FY 2025) | •••• | •••• | -22.0% | •••• | New Delhi, Delhi, India |
| Sahrudaya Health Care (Srikakulam) Private Limited | ₹68.15 Cr (FY 2025) | •••• | •••• | 5.0% | •••• | Madhapur Village, Telangana, India |
Peers are the five companies nearest above and the five nearest below Pharmalex India by revenue in the Healthcare industry (Preventive Healthcare Services), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Pharmalex India Private Limited
Pharmalex India Private Limited is audited by AGGARWAL MAHAVIR & ASSOCIATES for the financial year 2023.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| AGGARWAL MAHAVIR & ASSOCIATES | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Pharmalex India Private Limited
Pharmalex India has 2 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Christopher Gauglitz | Director | 04 Sep 2023 | 3 Years 1 Months | Current |
| Pawan Kumar Suri | Managing Director | 01 Jul 2019 | 7 Years 3 Months | Current |
Ownership and Shareholding of Pharmalex India Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Pharmalex India Private Limited
Pharmalex India Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Deals & Funding of Pharmalex India Private Limited
Pharmalex India Private Limited has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹19 Lakh; the latest was in September 2016.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2016 | Secondary share transfer | Undisclosed | Buyer: Pharmalex GmbH Seller: YES Multinational Holding Company G.m.b.H |
| Jan 2015 | Secondary share transfer | Undisclosed | Buyer: YES Multinational Holding Company G.m.b.H Seller: YES Pharmaceuticals Development Services G.m.b.H |
| Jul 2013 | Funding round | ₹19 Lakh | Investors: YES Pharmaceuticals Development Services G.m.b.H, Anregen Healthcare Private Limited |
Full deal history
All 3 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
MSME Payment Delays by Pharmalex India Private Limited
Pharmalex India Private Limited has 2 MSME Form 1 returns on record for the period ending Mar 2023, listing 158 overdue payments to 4 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (4 of 4)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Cliantha Research Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Tenet Health Edutech Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 2 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Pharmalex India Private Limited
Pharmalex India operates one associated brand: PharmaLex. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| CRO specializing in regulatory affairs and pharmacovigilance | pharmalex.com |
Employees and EPFO Compliance at Pharmalex India Private Limited
Pharmalex India Private Limited has a workforce of 267 employees as of Apr 08, 2024.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Pharmalex India Private Limited
Pharmalex India Private Limited has 14 board changes on record since 2017: 3 appointments and 11 cessations. The latest: Christopher . Gauglitz ceased to be Additional Director on 26 Sep 2023.
5 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Pharmalex India Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Pharmalex India Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Pharmalex India Private Limited
Pharmalex India has 3 GST registrations: 3 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAACY6178L1ZQ | Delhi | Active | 01 Jul 2017 |
| 09AAACY6178L1ZM | Uttar Pradesh | Active | 10 Apr 2020 |
| 36AAACY6178L1ZP | Telangana | Active | 04 Dec 2023 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Pharmalex India Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pharmalex India Private Limited
Pharmalex India is an active foreign private limited company based in New Delhi, Delhi, India. The company works in preventive health services, within the healthcare industry. It was incorporated on 23 May 2013 (13+ years old) and is registered under CIN U85100DL2013FTC252553.
Pharmalex India reported revenue of ₹74.75 Cr for FY 2025 (down 8% YoY).
Pharmalex India has 2 current directors:
- Pawan Kumar Suri - Managing Director
- Christopher Gauglitz - Director
Pharmalex India reported a net profit of ₹5.79 Cr (net margin 7.7%) and EBITDA of ₹9.31 Cr (EBITDA margin 12.5%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Pharmalex India is 10% over three years and 35% over five years. In the latest year (FY 2025) revenue fell 8%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Pharmalex India is 07AAACY6178L1ZQ, registered in Delhi. The company has 3 GST registrations in all, of which 3 are active. Other active GSTINs include 09AAACY6178L1ZM (Uttar Pradesh), 36AAACY6178L1ZP (Telangana).
The CIN (Corporate Identification Number) of Pharmalex India is U85100DL2013FTC252553. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Pharmalex India was incorporated on 23 May 2013, making it 13+ years old. It is registered with the Registrar of Companies, Delhi.
Pharmalex India has 3 deals on record (2 secondary share transfers, 1 funding round), with disclosed funding of ₹19 Lakh; the latest was in September 2016.
The peers of Pharmalex India by revenue are Surabhi Healthcare & Research Private Limited, Credent Connect N Care Limited, Goldwin Health Care Private Limited, Sada Sharada Tumor and Research Institute, Med Care 365 Medical Services Private Limited and 5 more, all in the Healthcare industry (Preventive Healthcare Services).
Christopher . Gauglitz ceased to be Additional Director on 26 Sep 2023. Laurent Couston ceased to be Additional Director on 26 Sep 2023. Rajesh Rajkumar Jain ceased to be Additional Director on 26 Sep 2023. Pharmalex India has 14 board changes on record in total.
Pharmalex India has 2 MSME Form 1 returns on record for the period ending Mar 2023, listing 158 overdue payments to 4 micro and small suppliers. The latest return was filed on 29 Aug 2023.